ClinicalTrials.gg
TerminatedNCT01687543ProbiEntUpdated Oct 5, 2017

Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients

An interventional study of L. plantarum 299 and L. plantarum 299v (+maltodextrin) and Maltodextrin in Clostridium Difficile Colonisation and Impact of Enteral Probiotics on Certain Lab Parameters, sponsored by Region Skane. Terminated at 4 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Region Skane · Not applicable, Interventional, and Prevention

How we know

Why this study was terminated
Too low inclusion rate and several sites did not comply

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Symptoms of Clostridium difficile infection is almost always induced as a complication to the use of antibiotics. Most ICU patients are given antibiotics.

Probiotics has the ability to improve conditions in the gut and it has been shown in some smaller studies that overgrowth of C. difficile can be reduced or prevented.

In this study the intention is to show with sufficient statistical power that a mixture of two otherwise well studied probiotic strains reduces or prevents the incidence of emerging colonisation with C. difficile in critical ill patients on antibiotics.

Half of the patients will be given a mixture of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v twice daily and the rest a placebo mixture.

Rectal swabs or faeces will be analysed for C.difficile and its toxins and the incidence of new cases will be compared for the two groups.

White blood cells (WBC´s), C reactive protein (CRP), lactate, urea, and creatinine will be followed daily as well as antibiotics, corticosteroids and all acid reducing medication.

Nutrition, enteral and total, and bowel habits will be recorded.

Read the detailed description

Infections with Clostridium difficile is considered to be the most frequent health care associated bacterial infection. Almost all cases are connected to the use of antibiotics.

The spectra of symptoms of infection reaches from loose stools to sepsis and death. It is estimated that about 5% of the population are carriers without symptoms.

Elderly people are more likely to be diagnosed with C. difficile infections and as about 50 % of ICU admissions (at least in Sweden) are patients aged 64 years or older C. difficile is also an ICU issue.

Probiotic bacteria given to antibiotic treated patients results in fever cases of infection with C. difficile as we and others have shown in some small studies. Due to a low statistical power in our former study this multicentre study is calculated to be large enough to fulfil statistical requirements.

Adult patients with an expected length of stay in intensive care for three days or more can be included.

Primary objective is to find emerging cases of colonisation with C. difficile and consequent symptoms of infection such as diarrhoea.

Cultures and toxin analyses will be taken at inclusion and every second day till day 13 and then every third or fourth day depending on length of ICU stay. Positive cases will be given antibiotics according to normal routines.

No other cultures are collected per protocol but all cultures will be recorded and results will be analysed in order to find any connection between treatment and reduction of secondary infections.

In our earlier small study we found an improved and normalised gut barrier function for those patients that were given probiotic bacteria compared to a worsened, scattered pattern for the placebo group. This is probably why we found that inflammatory parameters improved for the probiotics group while those parameters remained elevated for the control patients. The same goes for creatinine, urea and lactate. This is why we will record those parameters together with blood gas analyses in this expanded study.

Antibiotics and medication with corticosteroids, proton pump inhibitors or other acid reducing preparations, All nutritive prescriptions (enteral formulas and IV solutions as well as medical preparations containing glucose or fat) will be recorded and compared to actually given nutrients.

Bowel movements frequency and consistency will be recorded and compared between groups.

02

Conditions studied

  • Clostridium Difficile Colonisation
  • Impact of Enteral Probiotics on Certain Lab Parameters

Keywords

  • Clostridium difficile
  • WBC
  • CRP
  • Lactate
  • Urea
  • Creatinine
03

In context

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anticipated need for intensive care 3 days or longer
  • Patients condition allowing enteral nutrition to be started within 24 h from ICU admission
  • Antibiotics on-going or planned

Exclusion criteria

Exclusion Criteria:

  • Known positive test for Clostridium difficile within the last week
  • Known ulcers in the mouth, oropharynx, esophagus and stomach
  • Known immune deficiencies
  • Enteral nutrition contra indicated
  • Pancreatitis as admission diagnosis at the hospital or at the ICU
  • ICU admission earlier during this period of illness Patient being moribund
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Probiotics

    Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups

    Dietary Supplement: L. plantarum 299 and L. plantarum 299v (+maltodextrin)

  • Placebo comparator
    Control

    Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups

    Other: Maltodextrin

Interventions

  • Dietary supplementL. plantarum 299 and L. plantarum 299v (+maltodextrin)

    Drug page: Lactobacillus plantarum 299Studies of Lactobacillus plantarum 299Lactobacillus plantarum 299 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.

    Also known as: Lactobacillus plantarum 299, Lactobacillus plantarum 299v, Maltodextrin

  • OtherMaltodextrin

    A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.

06

What researchers measure

Primary outcomes

  1. Differences in emerging cases of Clostridium difficile

    Emerging cases of Clostridium difficile, identified as positive cultures and/or toxin tests

    Time frame: Throughout the ICU stay, expected mean LOS 10 days

Secondary outcomes

  1. White blood cells

    Samples taken at admission or inclusion and then daily

    Time frame: Throughout the ICU , expected mean LOS 10 days

  2. C Reactive Protein

    Samples taken at admission or inclusion and then daily

    Time frame: Throughout the ICU , expected mean LOS 10 days

  3. Creatinine

    Samples taken at admission or inclusion and then daily

    Time frame: Throughout the ICU , expected mean LOS 10 days

  4. Urea

    Samples taken at admission or inclusion and then daily

    Time frame: Throughout the ICU , expected mean LOS 10 days

  5. Lactate

    Samples taken at admission or inclusion and then daily

    Time frame: Throughout the ICU , expected mean LOS 10 days

  6. Ventilator days

    Records are held for how long the patients require mechanical ventilation

    Time frame: Throughout the ICU stay, expected mean LOS 10 days

  7. Length of stay ICU

    Length of stay is recorded for the ICU as well as for the Hospital stay

    Time frame: Length of ICU stay, about 10 days in accordance with a prior similar study

  8. Length of Hospital stay

    Length of stay is recorded for the Hospital as well as for the ICU stay

    Time frame: Within six months from date of ICU admission

  9. Survival

    For participating patients the status of survival or non survival at days 28 and 180 (six months) will be recorded

    Time frame: Six months

  10. Diarrhea and obstipation

    As ICU patients tend to display diarrhea as well as obstipation the frequency and consistency of stools will be recorded. Probiotics are anticipated to stabilise bowel function

    Time frame: Throughout the ICU stay, expected mean LOS 10 days

07

Study locations

4 sites
  • Intensive Care Unit, Helsingborg Hospital
    Helsingborg, SE 251 87, Sweden
  • Intensive Care Unit, Kristianstad Central hospital
    Kristianstad, SE 291 85, Sweden
  • Lund University Hospital
    Lund, SE 22185, Sweden
  • Dept of Anesthesia & Intensive Care, University Hospital of Norrland
    Umeå, SE-901 85, Sweden
08

References and documents

Publications

  • Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008 Sep;52(8):1096-102. doi: 10.1111/j.1399-6576.2008.01748.x. PubMed 18840110 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Jun 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2012
First posted
Sep 19, 2012
Start
Jun 2012
Primary completionActual
Jun 2017
CompletionActual
Oct 1, 2017
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01687543
Lead sponsor
Region Skane
Collaborators
Lund University
Responsible party
Sponsor
First posted
Sep 19, 2012
Start date
Jun 2012
Primary completion
Jun 2017
Completion
Oct 1, 2017
Last update
Oct 5, 2017

Study contacts

Bengt Klarin, MD, PhD
principal investigator · Lund University, Lund, Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactobacillus plantarum 299

Start the discussion